PIMCO CEO Dr. Mohamed El-Erian Voices Support for Children’s Cancer Hospital Egypt 57357 at ECN Iftar in Los Angeles, CA

Tag Archives: pediatric cancer

Dr. Mohamed A. El-Erian, CEO of PIMCO, a major global investment company, attended the Egypt Cancer Network 57357 (ECN) iftar in Los Angeles along with his wife and daughter. They were inspired by the work that is being done by ECN in support of Children’s Cancer Hospital Egypt 57357 (CCHE). Because of its effectiveness in delivering superior health services to children, they consider the hospital an impressive example of charity innovation and sustainability in Egypt.

Together with his daughter and wife, Dr. El-Erian stated that he was delighted “to support this world-class Egyptian hospital that provides comprehensive cancer care to children at no financial cost to them or their families.”

ECN extends its sincere appreciation to Dr. El-Erian and his family for their visit and for their generosity. The administrations of both ECN and Children’s Cancer Hospital Foundation (CCHF), both recipients of Dr. El-Erian’s humanitarian donation, are grateful that Dr. El-Erian shares their strategic vision to cure children regardless of their ability to pay. ECN and CCHF are equally grateful for Dr. El-Erian’s support of their tireless efforts to make CCHE be a world leader in pediatric cancer care. With Dr. El-Erian’s help, CCHE, by way of ECN and CCHF, is truly on the way to achieving its expansion goal to serve and cure more children in Egypt.

 

Dana-Farber/Children’s Hospital Cancer Center to partner with Egypt Cancer Network and Children’s Cancer Hospital Egypt

Creating Egypt-based fellowship training program for physicians from Egypt, the Middle East and North Africa Region

BOSTON – Dana-Farber/Children’s Hospital Cancer Center is announcing a partnership with the Egypt Cancer Network and Children’s Cancer Hospital Egypt in an effort to improve childhood cancer survival rates and outcomes within Egypt, the Middle East and North Africa. The organizations are collaborating to create an Egypt-based fellowship training program in pediatric oncology for physicians in those regions.

“Since beginning a twinning program between the Dana-Farber/Children’s Hospital Cancer Center and the Children’s Cancer Hospital Egypt in 2006, we have seen significant improvement in the outcome of pediatric cancer patients in Egypt,” said Mark Kieran, MD, PhD, director of medical neuro-oncology at Dana-Farber/Children’s Hospital Cancer Center and member of the medical advisory board for the Children’s Cancer Hospital Egypt 57357’s pediatric oncology fellowship program. “However, there is still a shortage of expertise and resources needed to treat children with cancer in this region.”

“The fellowship is designed to improve the childhood cancer survival rates and outcomes within Egypt, the Middle East and North Africa,” said Kieran. “This collaboration will allow the exchange of information, knowledge and experience for both doctors from the region and from the United States, providing the opportunity for the improvement of treatment and care practices.”

The collaboration will provide a formal fellowship framework for pediatric oncology training and mentoring for Egyptian, African and Middle Eastern pediatricians in line with international standards and will create a pool of qualified pediatric oncologists who can ensure continued progress in improving outcomes for children with cancer in this region.

As part of the fellowship, between 2 and 6 pediatric physicians from the Children’s Cancer Hospital Egypt will travel to Boston to work with specialists at Dana-Farber/Children’s Hospital Cancer Center (DF/CHCC).  In addition, DF/CHCC physicians will rotate at the Children’s Cancer Hospital Egypt to train oncologists there in the latest treatments and care techniques.

About the Dana-Farber / Children’s Hospital Cancer Center

Dana-Farber/Children’s Hospital Cancer Center (DF/CHCC) combines the strengths of Dana-Farber Cancer Institute, a world-class cancer institute, and Boston Children’s Hospital, an internationally known pediatric hospital. For over 60 years, these two Harvard Medical School affiliates have provided comprehensive care for children and adolescents with cancer. Committed to conducting research to better understand and treat childhood cancers, DF/CHCC is the Pediatric Oncology Experimental Therapeutics Investigator Consortium’s (POETIC) only Phase I Clinical Trial site in New England, and is home to one of the world’s most sophisticated and accomplished Pediatric Stem Cell Transplantation centers. DF/CHCC also offers comprehensive transitional and long-term survivorship programs to childhood cancer survivors of all ages.